

## **ASCO**<sup>°</sup> Guidelines



This algorithm is derived from recommendations in Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

## **ASCO**<sup>°</sup> Guidelines

## **Recommendations by Subtype**



**Abbreviations.** HNSCC, head and neck squamous cell carcinoma; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden

This algorithm is derived from recommendations in Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

www.asco.org/head-neck-cancer-guidelines ©American Society of Clinical Oncology 2022. All rights reserved. For licensing opportunities, contact <u>licensing@asco.org</u>